【月供股票名單】藍籌業績 [31.12.2020 派息] - 中國生物製藥(01177.HK)首三季純利18.5億人幣跌18% 季息2港仙 (SINO BIOPHARM 1-3Q Net Profit RMB1.85B, Down 18%; QoQ Div HK2 Cents 2020) ...... !

​中國生物製藥(01177.HK)  +0.060 (+0.902%)    沽空 $1.19億; 比率 9.305%   公布截至今年9月底止首三季業績，營業額181.26億元人民幣(下同)，按年跌6.2%。純利18.5億元，按年跌18%；每股盈利9.81分。派季度息2港仙。期內基本盈利為22.94億元，按年下跌11.7%。

期內新產品銷售收入佔集團總收入約36.7%，達到約66.59億元，較去年同期上升約66.9%；創新藥銷售額佔集團總收入約25%，去年同期佔比為約20%。

單計第三季，集團獲得臨床批件6件、生產批件11件及一致性評價獲批15個、申報臨床6件、一致性評價申報6個及申報生產2個。已累計有臨床批件、正在進行臨床試驗和申報生產的在研產品共398件，其中肝病用藥37件、抗腫瘤用藥190件、呼吸系統用藥22件、內分泌用藥20件、心腦血管用藥16件及其它類用藥113件。

​SINO BIOPHARM (01177.HK)  +0.060 (+0.902%)    Short selling $119.32M; Ratio 9.305%   announced the result for the first three quarters ended September 2020. The net profit amounted to RMB1.85 billion, down 18% yearly. EPS was 9.81 fen. A quarterly dividend of HK2 cents was declared.

Underlying profit was RMB2.294 billion for the period, down 11.7% annually.

http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1059937/latest-news